| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Payment of offering costs related to follow-on public offering | - | - | - | 0 |
| Net cash (used in) provided by financing activities | -60,895 | -65,226 | -66,850 | 1,939 |
| Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | 1,177 | 1,710 | 773 | -75 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 59,760 | 105,725 | 174,098 | -445,319 |
| Cash and cash equivalents at beginning of period | 629,755 | - | - | - |
| Cash and cash equivalents at end of period | 689,515 | - | - | - |
Guardant Health, Inc. (GH)
Guardant Health, Inc. (GH)